RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
brand name Zytorvi for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of head and neck cancer. Loqtorzi, a novel anti-PD-1 monoclonal antibody, is a new biological entity that has been developed by Coherus in collaboration with China-based Junshi Biosciences. In October 2023, CHRS announced the FDA's approval of Loqtorzi in combination with cisplatin gemcitabine for the first-line treatment of adults with RM-NPC. The drug was also approved as a monotherapy for treating adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Loqtorzi is the first and only FDA-approved immuno-oncology drug for this carcinoma indication. Consequently, Coherus launched Loqtorzi in the U.S. market in early 2024. The drug is also currently approved in other geographies, including the EU and the U.K. for treating the RM-NPC indication. Coherus as well as its partners plan to further e
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at Nomura from a "buy" rating to a "neutral" rating.MarketBeat
- Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- Heparin Market to Grow by USD 3.34 Billion (2024-2028), Driven by Coagulation Disorder Prevalence and AI Impacting Market Trends - Technavio [Yahoo! Finance]Yahoo! Finance
- Theranica Advances Migraine Care in 2024 Supported by New Research, an Expanded Indication, a new Chief Medical Officer, and Broader Insurance Coverage [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
RDY
Earnings
- 11/6/24 - Beat
RDY
Sec Filings
- 12/20/24 - Form 6-K
- 12/6/24 - Form 6-K
- 12/6/24 - Form 6-K
- RDY's page on the SEC website